Bio-Techne Aktie
WKN DE: A12ENG / ISIN: US09073M1045
07.01.2025 13:31:08
|
Bio-Techne Wins Second Claim Of Reverse Engineering By Miltenyi Biotec
(RTTNews) - Bio-Techne Corp. (TECH), a life sciences company, announced Tuesday that it has won a second claim of reverse engineering by Miltenyi Biotec B.V. & Co. KG, which may appeal the Court's ruling.
The company noted that Miltenyi commercialized antibodies developed based on information obtained by reverse engineering Bio-Techne's proprietary R&D Systems branded NKG2C/CD159c antibodies.
In a similar case from 2023, Miltenyi was found to have reversed engineered and commercialized Bio-Techne's proprietary R&D Systems branded TIGIT and CCR-7 antibodies.
Bio-Techne noted that it took legal action against Miltenyi in the Cologne Regional Court, Germany, after discovering that the variable regions of Miltenyi's NKG2C/CD159c antibodies were 100% identical to the R&D Systems antibodies.
The court found that Miltenyi has been marketing and selling these reverse engineered antibodies. The court also determined that Bio-Techne is entitled to monetary damages related to sales of the reverse engineered antibodies, and reimbursement for Bio-Techne's costs incurred, among others.
Kim Kelderman, President and Chief Executive Officer of Bio-Techne, said, "We have spent almost five decades developing our extensive catalogue of solutions that enable the scientific community to discover novel biological insights and develop advanced therapeutics. We will continue to vigorously defend our intellectual property against Miltenyi and any other potential offenders."
For More Such Health News, visit rttnews.com

Wenn Sie mehr über das Thema Aktien erfahren wollen, finden Sie in unserem Ratgeber viele interessante Artikel dazu!
Jetzt informieren!
Nachrichten zu Bio-Techne Corpmehr Nachrichten
16:03 |
NYSE-Handel: S&P 500-Börsianer greifen zum Start des Mittwochshandels zu (finanzen.at) | |
05.06.25 |
S&P 500-Papier Bio-Techne-Aktie: So viel hätten Anleger mit einem Investment in Bio-Techne von vor einem Jahr verloren (finanzen.at) | |
29.05.25 |
S&P 500-Wert Bio-Techne-Aktie: So viel hätten Anleger an einem Bio-Techne-Investment von vor 10 Jahren verdient (finanzen.at) | |
22.05.25 |
S&P 500-Wert Bio-Techne-Aktie: So viel Verlust hätte ein Bio-Techne-Investment von vor 5 Jahren eingefahren (finanzen.at) | |
15.05.25 |
S&P 500-Titel Bio-Techne-Aktie: So viel Verlust hätte ein Bio-Techne-Investment von vor 3 Jahren eingebracht (finanzen.at) | |
14.05.25 |
Zuversicht in New York: S&P 500 bewegt sich zum Ende des Mittwochshandels im Plus (finanzen.at) | |
14.05.25 |
Börse New York: S&P 500 liegt nachmittags im Plus (finanzen.at) | |
14.05.25 |
Optimismus in New York: S&P 500 am Mittag freundlich (finanzen.at) |
Analysen zu Bio-Techne Corpmehr Analysen
Aktien in diesem Artikel
Bio-Techne Corp | 44,60 | 0,45% |
|